published_date,market,entry_time,exit_time,ticker,direction,shares,entry_price,exit_price,target_price,stop_price,hit_target,hit_stop,pnl,pnl_pct,capital_after,news_event,link,runid,rundate
2025-05-30 07:30:00+00:00,pre_market,2025-05-30 10:26:00-04:00,2025-05-30 15:12:00+00:00,TGTX,LONG,28,35.029998779296875,35.38029876708985,35.38029876708985,34.85484878540039,True,False,9.808399658203228,0.9808399658203228,10009.808399658203,clinical_study,https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-05-30 08:00:00+00:00,pre_market,2025-05-30 10:26:00-04:00,2025-05-30 14:28:00+00:00,MDAI,LONG,614,1.6292999982833862,1.6211534982919693,1.64559299826622,1.6211534982919693,False,True,-5.00195099472999,-0.4997049688684138,10004.806448663472,management_changes,https://www.globenewswire.com/news-release/2025/05/30/3091011/0/en/Spectral-AI-Announces-Appointment-of-Stanley-Micek-as-Chief-Operating-Officer.html,e0f76d50,2025-06-28 11:19:39
2025-05-30 08:00:00+00:00,pre_market,2025-05-30 10:26:00-04:00,2025-05-30 14:43:00+00:00,CHRS,LONG,1277,0.7832000255584717,0.7910320258140564,0.7910320258140564,0.7792840254306793,True,False,10.001464326381695,0.9996659483320416,10014.807912989854,company_regulatory_filings,https://www.globenewswire.com/news-release/2025/05/30/3091025/33333/en/Coherus-Completes-Strategic-Transformation-to-Coherus-Oncology-Focusing-Exclusively-on-Innovative-Cancer-Therapeutics.html,e0f76d50,2025-06-28 11:19:39
2025-05-30 10:47:00+00:00,pre_market,2025-05-30 10:26:00-04:00,2025-05-30 14:47:00+00:00,FBIO,LONG,534,1.875,1.89375,1.89375,1.865625,True,False,10.012500000000024,0.9997695499494468,10024.820412989855,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/05/30/3091157/28889/en/Fortress-Biotech-Announces-Closing-of-Sale-of-Subsidiary-Checkpoint-Therapeutics.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 06:45:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:26:00+00:00,BNTX,LONG,8,113.09500122070312,112.52952621459961,114.22595123291016,112.52952621459961,False,True,-4.523800048828093,-0.45125995902792354,10020.296612941027,partnerships,https://www.globenewswire.com/news-release/2025/06/02/3091688/0/en/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 06:45:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:26:00+00:00,BNTX,LONG,8,113.09500122070312,112.52952621459961,114.22595123291016,112.52952621459961,False,True,-4.523800048828093,-0.45146368651260177,10015.772812892199,partnerships,https://www.globenewswire.com/news-release/2025/06/02/3091688/0/de/BioNTech-und-Bristol-Myers-Squibb-geben-globale-strategische-Partnerschaft-zur-gemeinsamen-Entwicklung-und-Kommerzialisierung-des-bispezifischen-Antik%C3%B6rperkandidaten-BNT327-in-eine.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 07:00:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:31:00+00:00,IMCR,SHORT,26,38.28499984741211,37.90214984893799,37.90214984893799,38.47642484664917,True,False,9.954099960327156,0.9938424269682257,10025.726912852526,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/02/3091717/0/en/Immunocore-to-present-at-the-2025-Jefferies-Global-Healthcare-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 07:30:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 15:06:00+00:00,INAB,LONG,7509,0.13349999487400055,0.13483499482274056,0.13483499482274056,0.13283249489963053,True,False,10.024514615088709,0.999879081310078,10035.751427467614,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091745/0/en/IN8bio-Presents-Positive-Phase-1-Data-of-INB-200-in-Newly-Diagnosed-GBM-Demonstrating-Prolonged-Progression-Free-Survival.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 08:00:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 15:17:00+00:00,TGTX,LONG,28,35.01240158081055,35.36252559661865,35.36252559661865,34.837339572906494,True,False,9.803472442626969,0.976854848735601,10045.554899910241,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/02/3091817/8790/en/TG-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 08:00:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:26:00+00:00,BCAB,LONG,2074,0.48420000076293945,0.4817790007591248,0.48904200077056886,0.4817790007591248,False,True,-5.02115400791164,-0.49983839199928165,10040.53374590233,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091818/0/en/BioAtla-Presents-Phase-2-Ozuriftamab-Vedotin-Oz-V-Clinical-Trial-Data-Demonstrating-Compelling-Antitumor-Activity-in-HPV-Associated-Oropharyngeal-Squamous-Cell-Carcinoma-HPV-OPSCC-.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 08:00:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:49:00+00:00,HUMA,LONG,370,2.7100000381469727,2.6964500379562377,2.7371000385284425,2.6964500379562377,False,True,-5.013500070571926,-0.49932605152768883,10035.520245831758,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091791/0/en/Humacyte-Clinical-Results-in-High-Risk-Dialysis-Patients-from-V007-Pivotal-Phase-3.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 08:05:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:29:00+00:00,IMNN,LONG,368,2.7249999046325684,2.752249903678894,2.752249903678894,2.7113749051094054,True,False,10.027999649047793,0.9992506022010081,10045.548245480806,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091830/0/en/IMUNON-CEO-RECAPS-A-YEAR-OF-CLINICAL-ACHIEVEMENT-AND-SOLID-FUNDAMENTALS.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 08:35:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:28:00+00:00,DYAI,LONG,975,1.0299999713897705,1.0402999711036682,1.0402999711036682,1.0248499715328216,True,False,10.04249972105028,0.9996965298104165,10055.590745201856,management_changes,https://www.globenewswire.com/news-release/2025/06/02/3091869/0/en/Dyadic-Announces-Leadership-Change-as-Part-of-Ongoing-Strategic-Shift-to-Focus-on-High-Demand-Ancillary-Proteins-for-Life-Sciences-Nutrition-and-Industrial-Applications.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 09:15:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 15:33:00+00:00,ALVO,LONG,88,11.34000015258789,11.283300151824951,11.453400154113769,11.283300151824951,False,True,-4.989600067138653,-0.4962015851251205,10050.601145134719,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/02/3091962/0/en/Alvotech-Meets-Investors-and-Presents-at-the-Jefferies-Global-Healthcare-Conference-2025-in-New-York-NY.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 09:15:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 15:09:00+00:00,ALVO,SHORT,88,11.34000015258789,11.396700153350828,11.226600151062012,11.396700153350828,False,True,-4.989600067138497,-0.4964479233716139,10045.61154506758,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/02/3091962/0/is/Alvotech-fundar-me%C3%B0-fj%C3%A1rfestum-%C3%A1-%C3%A1rlegri-heilbrig%C3%B0isr%C3%A1%C3%B0stefnu-Jefferies-fj%C3%A1rfestingabankans-%C3%AD-New-York-og-flytur-kynningu.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 09:15:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 15:33:00+00:00,ALVO,LONG,88,11.34000015258789,11.283300151824951,11.453400154113769,11.283300151824951,False,True,-4.989600067138653,-0.496694506327846,10040.621945000443,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/02/3091963/0/en/Alvotech-Meets-Investors-and-Presents-at-the-Jefferies-Global-Healthcare-Conference-2025-in-New-York-NY.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 09:29:00+00:00,pre_market,2025-06-02 10:26:00-04:00,2025-06-02 14:32:00+00:00,IOVA,LONG,568,1.7649999856948853,1.7561749857664108,1.782649985551834,1.7561749857664108,False,True,-5.012599959373464,-0.4992320183780451,10035.60934504107,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091973/0/en/The-Journal-of-Clinical-Oncology-Publishes-Five-year-Analysis-of-Amtagvi-lifileucel-in-Patients-with-Advanced-Melanoma.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 16:05:00+00:00,regular_market,2025-06-02 12:10:00-04:00,2025-06-02 16:20:00+00:00,XFOR,LONG,253,3.962599992752075,3.942786992788315,4.002225992679596,3.942786992788315,False,True,-5.012688990831325,-0.49949024702802547,10030.596656050238,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/02/3092328/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-02 16:20:00+00:00,regular_market,2025-06-02 12:25:00-04:00,2025-06-02 16:28:00+00:00,VXRT,SHORT,2209,0.45399999618530273,0.4562699961662292,0.4494599962234497,0.4562699961662292,False,True,-5.0144299578665805,-0.4999134278659271,10025.582226092372,annual_meetings_shareholder_rights,https://www.globenewswire.com/news-release/2025/06/02/3092346/25416/en/Vaxart-Announces-Adjournment-of-Annual-Meeting-of-Stockholders.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 01:00:00+00:00,after_market,2025-06-03 10:26:00-04:00,2025-06-03 16:56:00-04:00,ADXN,SHORT,124,8.079999923706055,8.079999923706055,7.999199924468994,8.120399923324584,False,False,0.0,0.0,10025.582226092372,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/03/3092426/0/en/Addex-Convenes-Annual-General-Meeting-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 04:00:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 16:56:00-04:00,OCS,LONG,51,19.3700008392334,19.440000534057617,19.563700847625732,19.27315083503723,False,False,3.5699844360351562,0.35608749252926064,10029.152210528408,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/03/3092473/0/en/Oculis-to-Participate-in-Upcoming-June-Investor-Conferences.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 04:00:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 16:56:00-04:00,OCS,LONG,51,19.3700008392334,19.440000534057617,19.563700847625732,19.27315083503723,False,False,3.5699844360351562,0.35596073936214234,10032.722194964443,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/03/3092472/0/en/Oculis-to-Participate-in-Upcoming-June-Investor-Conferences.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 07:00:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:34:00+00:00,AKRO,SHORT,19,51.04999923706055,51.305249233245846,50.53949924468994,51.305249233245846,False,True,-4.849749927520676,-0.48339322401998036,10027.872445036923,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/03/3092591/0/en/Akero-Therapeutics-to-Present-at-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 07:05:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:36:00+00:00,KBLB,LONG,12118,0.08275000005960464,0.08357750006020069,0.08357750006020069,0.08233625005930661,True,False,10.027645007222883,0.9999773194348764,10037.900090044146,press_releases,https://www.globenewswire.com/news-release/2025/06/03/3092617/0/en/Kraig-Biocraft-Laboratories-Issues-a-Letter-to-Shareholders-on-Recent-Advancements-and-Potential-Recombinant-Spider-Silk-Deliveries-in-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 08:00:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:28:00+00:00,JSPR,SHORT,164,6.099999904632568,6.13049990415573,6.038999905586243,6.13049990415573,False,True,-5.001999921798543,-0.49831138753409765,10032.898090122348,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092716/0/en/Jasper-Therapeutics-Announces-Briquilimab-Presentations-at-the-European-Academy-of-Allergy-and-Clinical-Immunology-EAACI-Annual-Congress.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 08:05:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:26:00+00:00,IMNN,LONG,394,2.541100025177002,2.528394525051117,2.566511025428772,2.528394525051117,False,True,-5.005967049598736,-0.4989552375227694,10027.892123072748,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092724/0/en/IMUNON-Announces-Data-Presented-at-ASCO-Reinforces-Unprecedented-Overall-Survival-in-Ovarian-Cancer-Phase-2-Study.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 09:15:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:27:00+00:00,RENB,LONG,3166,0.3167000114917755,0.3151165114343166,0.3198670116066933,0.3151165114343166,False,True,-5.013361181914835,-0.4999416747194364,10022.878761890834,patents,https://www.globenewswire.com/news-release/2025/06/03/3092863/0/en/Renovaro-Secures-Key-U-S-Patent-to-Strengthen-AI-Driven-Drug-Discovery-and-Diagnostics-Platform.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 09:15:00+00:00,pre_market,2025-06-03 10:26:00-04:00,2025-06-03 14:28:00+00:00,EVAX,LONG,383,2.615000009536743,2.6019250094890594,2.6411500096321108,2.6019250094890594,False,True,-5.007725018262898,-0.49962941159214236,10017.871036872571,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092866/0/en/Evaxion-receives-grant-funding-to-design-new-polio-vaccine.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 14:55:00+00:00,regular_market,2025-06-03 11:00:00-04:00,2025-06-03 15:20:00+00:00,IMMX,LONG,401,2.4944000244140625,2.5193440246582033,2.5193440246582033,2.4819280242919923,True,False,10.002544097900454,0.9984700402994106,10027.873580970472,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093133/0/en/Immix-Biopharma-Announces-Primary-Endpoint-Met-in-positive-NXC-201-Interim-Results-Presented-at-ASCO-Enabling-Path-to-Best-in-Class-Therapy-for-relapsed-refractory-AL-Amyloidosis.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 16:01:00+00:00,regular_market,2025-06-03 12:05:00-04:00,2025-06-03 16:11:00+00:00,BCAX,SHORT,92,10.800000190734863,10.854000191688536,10.692000188827514,10.854000191688536,False,True,-4.968000087737913,-0.49541909833860537,10022.905580882734,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/03/3093174/0/en/Bicara-Therapeutics-to-Present-at-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 16:05:00+00:00,regular_market,2025-06-03 12:10:00-04:00,2025-06-03 16:16:00+00:00,ANAB,LONG,41,23.969999313354492,23.850149316787718,24.209699306488037,23.850149316787718,False,True,-4.913849859237747,-0.49026201230611366,10017.991731023496,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093190/0/en/Anaptys-Announces-Positive-Rosnilimab-Data-Updated-Through-Six-Months-in-Robust-Phase-2b-Trial-in-RA.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 16:05:00+00:00,regular_market,2025-06-03 12:10:00-04:00,2025-06-03 16:42:00+00:00,WINT,LONG,1268,0.789900004863739,0.7977990049123764,0.7977990049123764,0.7859505048394203,True,False,10.015932061672245,0.999794402969522,10028.007663085169,corporate_action,https://www.globenewswire.com/news-release/2025/06/03/3093194/0/en/Windtree-Announces-Plan-for-Cryptocurrency-Treasury-Policy.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 16:30:00+00:00,regular_market,2025-06-03 12:35:00-04:00,2025-06-03 16:48:00+00:00,DBVT,LONG,125,8.00790023803711,7.967860736846924,8.08797924041748,7.967860736846924,False,True,-5.004937648773189,-0.49909591385706953,10023.002725436396,company_regulatory_filings,https://www.globenewswire.com/news-release/2025/06/03/3093208/0/fr/DBV-Technologies-publie-un-amendement-%C3%A0-son-Document-d-enregistrement-universel-2024.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 16:30:00+00:00,regular_market,2025-06-03 12:35:00-04:00,2025-06-03 16:48:00+00:00,DBVT,SHORT,125,8.00790023803711,7.927821235656738,7.927821235656738,8.047939739227294,True,False,10.009875297546378,0.9986902699470785,10033.012600733942,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/03/3093208/0/en/DBV-Technologies-announces-the-filing-of-an-addendum-to-the-2024-Universal-Registration-Document.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 17:00:00+00:00,regular_market,2025-06-03 13:05:00-04:00,2025-06-03 16:56:00-04:00,OCS,LONG,51,19.31999969482422,19.440000534057617,19.51319969177246,19.223399696350096,False,False,6.12004280090332,0.6099905426666784,10039.132643534846,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/03/3093227/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html,e0f76d50,2025-06-28 11:19:39
2025-06-03 17:17:00+00:00,regular_market,2025-06-03 13:20:00-04:00,2025-06-03 17:27:00+00:00,TSHA,LONG,346,2.8949999809265137,2.880524981021881,2.9239499807357787,2.880524981021881,False,True,-5.00834996700293,-0.49888273667031224,10034.124293567842,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093240/0/en/Taysha-Gene-Therapies-Announces-Details-for-Oral-Presentations-at-the-2025-IRSF-Rett-Syndrome-Scientific-Meeting-Reviewing-Recent-Updates-from-the-TSHA-102-Clinical-Program.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 01:00:00+00:00,after_market,2025-06-04 10:26:00-04:00,2025-06-04 17:11:00+00:00,VALN,LONG,159,6.292799949645996,6.261335949897766,6.355727949142456,6.261335949897766,False,True,-5.00277595996864,-0.4985762397995769,10029.121517607873,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/04/3093286/0/en/Valneva-Announces-Availability-of-Documentation-for-its-Combined-Shareholder-Meeting-and-Provides-Corporate-Update.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 01:00:00+00:00,after_market,2025-06-04 10:26:00-04:00,2025-06-04 17:11:00+00:00,VALN,LONG,159,6.292799949645996,6.261335949897766,6.355727949142456,6.261335949897766,False,True,-5.00277595996864,-0.49882494206350914,10024.118741647904,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/04/3093286/0/fr/Valneva-annonce-la-mise-%C3%A0-disposition-des-documents-pr%C3%A9paratoires-%C3%A0-son-Assembl%C3%A9e-G%C3%A9n%C3%A9rale-Mixte-et-une-%C3%A9volution-de-son-%C3%A9quipe-de-direction.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 06:55:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 16:40:00+00:00,RVVTF,SHORT,44120,0.02271999977529049,0.02283359977416694,0.022492799777537584,0.02283359977416694,False,True,-5.012031950428941,-0.4999972645580407,10019.106709697475,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/04/3093409/0/en/Revive-Therapeutics-Advances-with-Next-Generation-Bucillamine-Development.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 07:45:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 14:53:00+00:00,ALVO,LONG,87,11.489999771118164,11.432549772262574,11.604899768829346,11.432549772262574,False,True,-4.998149900436358,-0.49886182922861355,10014.108559797038,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/04/3093479/0/is/Alvotech-l%C3%BDkur-vi%C3%B0-kaup-%C3%A1-ranns%C3%B3knara%C3%B0st%C3%B6%C3%B0u-Xbrane-og-fyrirhuga%C3%B0ri-hli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Cimzia.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 07:45:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 14:53:00+00:00,ALVO,LONG,87,11.489999771118164,11.432549772262574,11.604899768829346,11.432549772262574,False,True,-4.998149900436358,-0.4991108165635523,10009.1104098966,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/04/3093479/0/en/Alvotech-Completes-Acquisition-of-Xbrane-R-D-Organization-and-biosimilar-candidate-to-Cimzia.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 08:00:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 14:29:00+00:00,ELTX,LONG,117,8.5,8.585,8.585,8.4575,True,False,9.9450000000001,0.9935947944151847,10019.0554098966,financing_agreements,https://www.globenewswire.com/news-release/2025/06/04/3093507/0/en/Elicio-Therapeutics-Secures-10-Million-in-Financing.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 11:32:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 14:53:00+00:00,ALVO,LONG,87,11.489999771118164,11.432549772262574,11.604899768829346,11.432549772262574,False,True,-4.998149900436358,-0.49886438351257106,10014.057259996163,initial_public_offerings,https://www.globenewswire.com/news-release/2025/06/04/3093802/0/is/Alvotech-r%C3%A1%C3%B0gerir-%C3%BAtbo%C3%B0-til-stofnanafj%C3%A1rfesta-%C3%A1-um-7-5-millj%C3%B3num-s%C3%A6nskra-heimildarsk%C3%ADrteina-og-hlutabr%C3%A9fum.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 11:32:00+00:00,pre_market,2025-06-04 10:26:00-04:00,2025-06-04 14:53:00+00:00,ALVO,LONG,87,11.489999771118164,11.432549772262574,11.604899768829346,11.432549772262574,False,True,-4.998149900436358,-0.4991133733978942,10009.059110095726,shares_issue,https://www.globenewswire.com/news-release/2025/06/04/3093802/0/en/Alvotech-intends-to-carry-out-a-private-placement-of-approximately-7-5-million-SDRs-and-ordinary-shares.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 16:05:00+00:00,regular_market,2025-06-04 12:10:00-04:00,2025-06-04 17:20:00+00:00,RAPT,LONG,981,1.0199999809265137,1.014899981021881,1.030199980735779,1.014899981021881,False,True,-5.003099906444593,-0.49985716453589246,10004.056010189282,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/04/3093978/0/en/RAPT-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 16:32:00+00:00,regular_market,2025-06-04 12:35:00-04:00,2025-06-04 16:39:00+00:00,DBVT,SHORT,125,7.974999904632568,8.01487490415573,7.895249905586242,8.01487490415573,False,True,-4.984374940395275,-0.4982354092498696,9999.071635248887,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/04/3094008/0/fr/Information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-mai-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 16:32:00+00:00,regular_market,2025-06-04 12:35:00-04:00,2025-06-04 16:39:00+00:00,DBVT,LONG,125,7.974999904632568,8.054749903678895,8.054749903678895,7.935124905109405,True,False,9.968749880790773,0.9969675430315726,10009.040385129678,voting_rights,https://www.globenewswire.com/news-release/2025/06/04/3094008/0/en/Information-Regarding-the-Total-Number-of-Voting-Rights-and-Total-Number-of-Shares-of-the-Company-as-of-May-30-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-04 22:29:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 14:49:00+00:00,ALVO,SHORT,91,10.880000114440918,10.771200113296509,10.771200113296509,10.934400115013121,True,False,9.900800104141261,0.9891857484010925,10018.94118523382,shares_issue,https://www.globenewswire.com/news-release/2025/06/05/3094086/0/en/Alvotech-has-carried-out-a-private-placement-of-7-500-000-SDRs-and-ordinary-shares-at-a-price-of-SEK-100-00-per-SDR-and-ISK-1320-83-per-ordinary-share-raising-gross-proceeds-of-SEK.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 01:30:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 15:47:00+00:00,VALN,LONG,161,6.210000038146973,6.272100038528443,6.272100038528443,6.178950037956238,True,False,9.998100061416672,0.9979198277111492,10028.939285295237,voting_rights,https://www.globenewswire.com/news-release/2025/06/05/3094100/0/en/Valneva-SE-Declaration-of-shares-and-voting-rights-May-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 01:30:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 15:47:00+00:00,VALN,LONG,161,6.210000038146973,6.272100038528443,6.272100038528443,6.178950037956238,True,False,9.998100061416672,0.9969249765103492,10038.937385356654,voting_rights,https://www.globenewswire.com/news-release/2025/06/05/3094100/0/fr/Valneva-SE-D%C3%A9claration-d-actions-et-de-droits-de-vote-mai-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 02:55:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 14:43:00+00:00,ALVO,LONG,92,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,False,True,-5.004800052642835,-0.4985388254281884,10033.932585304012,partnerships,https://www.globenewswire.com/news-release/2025/06/05/3094121/0/is/Alvotech-og-Dr-Reddys-ganga-til-samstarfs-um-%C3%BEr%C3%B3un-hli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-krabbameinslyfi%C3%B0-Keytruda.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 02:55:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 14:43:00+00:00,ALVO,LONG,92,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,False,True,-5.004800052642835,-0.4987874903577696,10028.92778525137,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094122/0/en/Alvotech-and-Dr-Reddy-s-Enter-into-Collaboration-to-Co-Develop-Biosimilar-Candidate-to-Keytruda-pembrolizumab.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 02:55:00+00:00,after_market,2025-06-05 10:26:00-04:00,2025-06-05 14:43:00+00:00,ALVO,LONG,92,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,False,True,-5.004800052642835,-0.49903640347305506,10023.922985198727,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094121/0/en/Alvotech-and-Dr-Reddy-s-Enter-into-Collaboration-to-Co-Develop-Biosimilar-Candidate-to-Keytruda-pembrolizumab.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 04:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 18:57:00+00:00,OCS,SHORT,51,19.420000076293945,19.517100076675412,19.225800075531005,19.517100076675412,False,True,-4.952100019454797,-0.49402813915939314,10018.970885179273,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/05/3094138/0/en/Oculis-Publishes-Results-of-2025-Annual-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 04:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 18:57:00+00:00,OCS,SHORT,51,19.420000076293945,19.517100076675412,19.225800075531005,19.517100076675412,False,True,-4.952100019454797,-0.4942723235956571,10014.018785159818,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/05/3094142/0/en/Oculis-Publishes-Results-of-2025-Annual-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 04:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 18:57:00+00:00,OCS,SHORT,51,19.420000076293945,19.517100076675412,19.225800075531005,19.517100076675412,False,True,-4.952100019454797,-0.4945167495385084,10009.066685140364,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/05/3094138/0/is/Oculis-birtir-ni%C3%B0urst%C3%B6%C3%B0ur-a%C3%B0alfundar-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 06:30:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 17:31:00+00:00,ICCC,LONG,147,6.800000190734863,6.766000189781189,6.868000192642212,6.766000189781189,False,True,-4.998000140190119,-0.4993472715703091,10004.068685000173,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/05/3094204/0/en/ImmuCell-to-Hold-Virtual-Only-Annual-Meeting-of-Stockholders.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 07:02:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:27:00+00:00,OCGN,LONG,995,1.0049999952316284,0.9999749952554703,1.0150499951839447,0.9999749952554703,False,True,-4.999874976277338,-0.4997841511998027,9999.068810023895,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094247/0/en/Ocugen-Inc-Announces-Signing-of-Binding-Term-Sheet-for-the-License-of-OCU400-Modifier-Gene-Therapy-for-Retinitis-Pigmentosa-in-Korea.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 07:30:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:26:00+00:00,OVID,LONG,3154,0.31700000166893005,0.3154150016605854,0.3201700016856194,0.3154150016605854,False,True,-4.999090026319062,-0.4999555579923163,9994.069719997577,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094269/0/en/Ovid-Therapeutics-to-Host-Investor-and-Media-Event-Thursday-June-12-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 08:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:35:00+00:00,ANVS,LONG,329,3.0320000648498535,3.016840064525604,3.0623200654983522,3.016840064525604,False,True,-4.987640106678038,-0.4990599672021546,9989.082079890899,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/05/3094306/0/en/Annovis-to-Host-Webinar-and-Live-Q-A-on-June-24-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 08:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:30:00+00:00,IMNN,SHORT,670,1.4902000427246094,1.4976510429382324,1.4752980422973632,1.4976510429382324,False,True,-4.992170143127406,-0.49976265118265295,9984.089909747772,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/05/3094318/0/en/IMUNON-to-Present-at-the-Zacks-SCR-Life-Sciences-Virtual-Investor-Forum-on-June-12th.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 08:00:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:28:00+00:00,PCRX,LONG,37,26.639999389648438,26.506799392700195,26.906399383544922,26.506799392700195,False,True,-4.9283998870849715,-0.49362535109717154,9979.161509860687,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/05/3094300/0/en/Pacira-BioSciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 08:19:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 15:03:00+00:00,BMRA,LONG,314,3.1700000762939453,3.1541500759124754,3.2017000770568846,3.1541500759124754,False,True,-4.976900119781544,-0.4987292885142435,9974.184609740905,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094356/0/en/Biomerica-s-inFoods-IBS-Clinical-Study-Results-Published-in-June-Issue-of-Gastroenterology.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 11:45:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 15:47:00+00:00,VALN,LONG,160,6.210000038146973,6.272100038528443,6.272100038528443,6.178950037956238,True,False,9.936000061035202,0.996171662125803,9984.120609801941,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094602/0/fr/Valneva-annonce-des-r%C3%A9sultats-positifs-de-Phase-2-%C3%A0-six-mois-sur-la-persistance-des-anticorps-et-l-innocuit%C3%A9-de-son-vaccin-%C3%A0-dose-unique-contre-le-chikungunya-IXCHIQ-chez-les-enfan.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 11:45:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 15:47:00+00:00,VALN,SHORT,160,6.210000038146973,6.241050038337707,6.147900037765503,6.241050038337707,False,True,-4.968000030517459,-0.49759014586022826,9979.152609771423,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094602/0/en/Valneva-Reports-Positive-Six-Month-Antibody-Persistence-and-Safety-Phase-2-Results-in-Children-for-its-Single-Shot-Chikungunya-Vaccine-IXCHIQ.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 12:05:00+00:00,pre_market,2025-06-05 10:26:00-04:00,2025-06-05 14:34:00+00:00,SCLX,LONG,146,6.800000190734863,6.868000192642212,6.868000192642212,6.766000189781189,True,False,9.92800027847289,0.9948740806660833,9989.080610049896,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094624/0/en/Scilex-Holding-Company-Announces-Publication-on-GLOPERBA-Dosing-Adjustments-in-Peer-Review-Journal.html,e0f76d50,2025-06-28 11:19:39
2025-06-05 16:01:00+00:00,regular_market,2025-06-05 12:05:00-04:00,2025-06-05 16:10:00+00:00,NTLA,LONG,127,7.84499979019165,7.805774791240692,7.923449788093567,7.805774791240692,False,True,-4.981574866771707,-0.4987020388803153,9984.099035183124,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/05/3094754/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 01:00:00+00:00,after_market,2025-06-06 10:26:00-04:00,2025-06-06 15:28:00+00:00,ADXN,LONG,114,8.739999771118164,8.827399768829347,8.827399768829347,8.696299772262574,True,False,9.963599739074812,0.9979468056119961,9994.062634922198,clinical_study,https://www.globenewswire.com/news-release/2025/06/06/3094874/0/en/Addex-GABAB-PAM-Candidate-Demonstrates-Robust-Anti-Tussive-Activity-in-Multiple-Chronic-Cough-Preclinical-Models.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 07:30:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:52:00+00:00,TGTX,SHORT,24,40.0,40.199999999999996,39.6,40.199999999999996,False,True,-4.799999999999898,-0.48028516283531025,9989.2626349222,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095022/8790/en/TG-Therapeutics-to-Participate-in-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:00:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:42:00+00:00,ARQT,LONG,72,13.829999923706055,13.968299922943116,13.968299922943116,13.760849924087525,True,False,9.957599945068395,0.9968303276216693,9999.220234867267,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095048/0/en/Arcutis-to-Present-New-Long-Term-Results-of-ZORYVE-roflumilast-Cream-at-the-2025-Revolutionizing-Atopic-Dermatitis-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:00:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:38:00+00:00,TSHA,LONG,336,2.9749999046325684,2.9601249051094056,3.0047499036788943,2.9601249051094056,False,True,-4.997999839782679,-0.4998389596775417,9994.222235027484,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095044/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:05:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:41:00+00:00,CADL,LONG,172,5.78000020980835,5.837800211906433,5.837800211906433,5.751100208759308,True,False,9.94160036087041,0.9947347704584109,10004.163835388355,management_changes,https://www.globenewswire.com/news-release/2025/06/06/3095060/0/en/Candel-Therapeutics-Appoints-Maha-Radhakrishnan-M-D-to-its-Board-of-Directors.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:30:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 15:05:00+00:00,ALVO,LONG,93,10.680000305175781,10.786800308227539,10.786800308227539,10.626600303649901,True,False,9.93240028381347,0.9928266317149832,10014.096235672168,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095069/0/en/Alvotech-Participates-in-the-Goldman-Sachs-Global-Healthcare-Conference-in-Miami.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:30:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 15:05:00+00:00,ALVO,LONG,93,10.680000305175781,10.786800308227539,10.786800308227539,10.626600303649901,True,False,9.93240028381347,0.9918419046575885,10024.028635955981,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095069/0/is/Alvotech-tekur-%C3%BE%C3%A1tt-%C3%AD-%C3%A1rlegri-heilbrig%C3%B0isr%C3%A1%C3%B0stefnu-Goldman-Sachs-fj%C3%A1rfestingabankans-%C3%AD-Miami.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 08:30:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 15:05:00+00:00,ALVO,LONG,93,10.680000305175781,10.786800308227539,10.786800308227539,10.626600303649901,True,False,9.93240028381347,0.9908591290517823,10033.961036239794,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095070/0/en/Alvotech-Meets-Investors-and-Presents-at-the-Goldman-Sachs-Global-Healthcare-Conference-in-Miami.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 09:30:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:45:00+00:00,BMRA,SHORT,316,3.1700000762939453,3.1858500766754148,3.138300075531006,3.1858500766754148,False,True,-5.008600120544344,-0.4991647966794683,10028.95243611925,management_changes,https://www.globenewswire.com/news-release/2025/06/06/3095149/0/en/Biomerica-Appoints-Eric-B-Chin-to-Board-of-Directors-and-Audit-Committee-Chair.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 09:39:00+00:00,pre_market,2025-06-06 10:26:00-04:00,2025-06-06 14:31:00+00:00,IMMX,LONG,468,2.140000104904175,2.1614001059532164,2.1614001059532164,2.129300104379654,True,False,10.015200490951472,0.9986287755121609,10038.967636610203,government_news,https://www.globenewswire.com/news-release/2025/06/06/3095161/0/en/Immix-Biopharma-Attends-FDA-CEO-Forum-in-Washington-DC.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 16:00:00+00:00,regular_market,2025-06-06 12:05:00-04:00,2025-06-06 17:00:00+00:00,ARQT,LONG,71,13.960000038146973,14.099600038528443,14.099600038528443,13.890200037956237,True,False,9.911600027084411,0.9873126785406392,10048.879236637287,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095428/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 16:05:00+00:00,regular_market,2025-06-06 12:10:00-04:00,2025-06-06 17:12:00+00:00,PYPD,LONG,309,3.25,3.23375,3.2825,3.23375,False,True,-5.021249999999961,-0.4996825896457136,10043.857986637287,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/06/3095438/0/en/PolyPid-to-Host-Conference-Call-and-Webcast-to-Discuss-D-PLEX-SHIELD-II-Phase-3-Trial-Topline-Results-on-Monday-June-9-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-06 16:30:00+00:00,regular_market,2025-06-06 12:35:00-04:00,2025-06-06 16:44:00+00:00,ORIC,LONG,102,9.789999961853027,9.887899961471557,9.887899961471557,9.741049962043762,True,False,9.985799961090073,0.9942195493380674,10053.843786598378,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095449/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-09 07:00:00+00:00,pre_market,2025-06-09 10:26:00-04:00,2025-06-09 14:32:00+00:00,INAB,SHORT,318,3.1600000858306885,3.1284000849723816,3.1284000849723816,3.1758000862598417,True,False,10.048800272941573,0.9994983497094387,10063.89258687132,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095724/0/en/IN8bio-Recognizes-Achievement-of-4-Years-in-Remission-for-Patient-Treated-with-INB-200-in-Glioblastoma-Trial.html,e0f76d50,2025-06-28 11:19:39
2025-06-09 07:30:00+00:00,pre_market,2025-06-09 10:26:00-04:00,2025-06-09 14:30:00+00:00,PYPD,LONG,269,3.740000009536743,3.7213000094890596,3.7774000096321108,3.7213000094890596,False,True,-5.030300012826881,-0.49983641711250704,10058.862286858493,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095757/0/en/PolyPid-Announces-Positive-Topline-Results-from-Phase-3-SHIELD-II-Trial-D-PLEX-Demonstrated-Significant-Reduction-in-Surgical-Site-Infections-and-Successfully-Met-Primary-and-All-K.html,e0f76d50,2025-06-28 11:19:39
2025-06-09 08:00:00+00:00,pre_market,2025-06-09 10:26:00-04:00,2025-06-09 14:32:00+00:00,HUMA,LONG,396,2.5399999618530273,2.5653999614715577,2.5653999614715577,2.527299962043762,True,False,10.058399848938016,0.999954026816623,10068.920686707432,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095788/0/en/Results-from-Humacyte-s-V007-Pivotal-Phase-3-AV-Access-Study-Highlighted-by-Presentation-at-the-Society-for-Vascular-Surgery-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-09 09:15:00+00:00,pre_market,2025-06-09 10:26:00-04:00,2025-06-09 17:28:00+00:00,LGVN,SHORT,812,1.2400000095367432,1.2462000095844268,1.2276000094413757,1.2462000095844268,False,True,-5.034400038719098,-0.4999940108144165,10063.886286668712,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/09/3095911/0/en/Longeveron-to-Participate-in-the-H-C-Wainwright-6th-Annual-Neuro-Perspectives-Hybrid-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-09 16:05:00+00:00,regular_market,2025-06-09 12:10:00-04:00,2025-06-09 18:09:00+00:00,OCS,LONG,50,19.860000610351562,19.760700607299803,20.058600616455077,19.760700607299803,False,True,-4.965000152587962,-0.4933481968258056,10058.921286516124,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/09/3096188/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 07:05:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 15:26:00+00:00,KBLB,LONG,11430,0.08799999952316284,0.08887999951839447,0.08887999951839447,0.08755999952554702,True,False,10.05839994549748,0.999948171279624,10068.979686461622,geographic_expansion,https://www.globenewswire.com/news-release/2025/06/10/3096501/0/en/Kraig-Biocraft-Laboratories-Announces-Senior-Management-Trip-to-Southeast-Asia-to-Oversee-Expansion-of-Spider-Silk-Production.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:00:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:26:00+00:00,WINT,LONG,1022,0.9848999977111816,0.9799754977226257,0.9947489976882935,0.9799754977226257,False,True,-5.032838988304161,-0.4998360454606071,10063.946847473318,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/10/3096594/0/en/Windtree-Announces-Transformational-Agreement-to-Acquire-Revenue-Generating-Environmental-Services-Business.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:00:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:26:00+00:00,MBX,LONG,86,11.645000457763672,11.586775455474854,11.761450462341308,11.586775455474854,False,True,-5.007350196838367,-0.49755332303802113,10058.93949727648,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3096537/0/en/MBX-Biosciences-to-Present-at-the-American-Diabetes-Association-85th-Scientific-Sessions.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:00:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:32:00+00:00,XFOR,SHORT,265,3.785099983215332,3.8040254831314084,3.747248983383179,3.8040254831314084,False,True,-5.015257477760244,-0.4985871004709945,10053.92423979872,,https://www.globenewswire.com/news-release/2025/06/10/3096587/0/en/X4-Pharmaceuticals-Granted-Fast-Track-Designation-for-Mavorixafor-for-the-Treatment-of-Chronic-Neutropenia-by-U-S-FDA.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:00:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:37:00+00:00,ARQT,SHORT,70,14.194999694824219,14.053049697875977,14.053049697875977,14.265974693298338,True,False,9.936499786376913,0.9883205352834289,10063.860739585098,,https://www.globenewswire.com/news-release/2025/06/10/3096580/0/en/Arcutis-Enrolls-First-Child-in-INTEGUMENT-INFANT-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Infants-with-Atopic-Dermatitis.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:00:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:27:00+00:00,MDAI,LONG,483,2.0799999237060547,2.0695999240875245,2.100799922943115,2.0695999240875245,False,True,-5.023199815750097,-0.4991324846131752,10058.837539769347,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/10/3096545/0/en/DeepView-System-highlighted-at-the-annual-British-Burn-Association-conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 08:45:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:31:00+00:00,IOVA,SHORT,410,2.448699951171875,2.4242129516601563,2.4242129516601563,2.460943450927734,True,False,10.039669799804681,0.9980944378623392,10068.877209569151,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/10/3096645/0/en/Iovance-Biotherapeutics-to-Present-at-Upcoming-Conference.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 09:01:00+00:00,pre_market,2025-06-10 10:26:00-04:00,2025-06-10 14:54:00+00:00,MYNZ,LONG,491,2.049999952316284,2.070499951839447,2.070499951839447,2.0397499525547027,True,False,10.065499765873007,0.9996645660061347,10078.942709335024,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3096780/0/en/Mainz-Biomed-Initiates-Feasibility-Study-of-Biomarker-Panel-in-Pancreatic-Cancer-Project.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 16:00:00+00:00,regular_market,2025-06-10 12:05:00-04:00,2025-06-10 16:29:00+00:00,INMB,LONG,125,8.050000190734863,8.130500192642211,8.130500192642211,8.009750189781188,True,False,10.062500238418481,0.9983686313742697,10089.005209573443,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3097127/0/en/XPro-Reduces-Amyloid-and-Enhances-Behavior-Post-Traumatic-Brain-Injury-in-an-Animal-Model-of-Alzheimer-s-Disease-Supported-by-Department-of-Defense.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 16:15:00+00:00,regular_market,2025-06-10 12:20:00-04:00,2025-06-10 17:13:00+00:00,CELU,LONG,525,1.9200999736785889,1.910499473810196,1.9393009734153748,1.910499473810196,False,True,-5.0402624309063,-0.4995797232935912,10083.964947142536,management_changes,https://www.globenewswire.com/news-release/2025/06/10/3097149/0/en/Celularity-Announces-Chief-Financial-Officer-Transition.html,e0f76d50,2025-06-28 11:19:39
2025-06-10 16:47:00+00:00,regular_market,2025-06-10 12:50:00-04:00,2025-06-10 17:11:00+00:00,VXRT,LONG,2536,0.397599995136261,0.39561199516057965,0.4015759950876236,0.39561199516057965,False,True,-5.041567938327857,-0.49995889164177143,10078.923379204209,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3097178/25416/en/Vaxart-to-Host-Conference-Call-on-June-11-at-8-30-AM-ET-to-Discuss-Topline-Results-from-Its-Phase-I-Norovirus-Trial.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 07:30:00+00:00,pre_market,2025-06-11 10:26:00-04:00,2025-06-11 14:31:00+00:00,OCGN,SHORT,847,1.1888999938964844,1.1948444938659666,1.1770109939575195,1.1948444938659666,False,True,-5.034991474151431,-0.4995564788735375,10073.888387730058,trade_show,https://www.globenewswire.com/news-release/2025/06/11/3097456/0/en/Ocugen-To-Present-at-BIO-International-Convention-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 07:30:00+00:00,pre_market,2025-06-11 10:26:00-04:00,2025-06-11 14:26:00+00:00,VXRT,LONG,1847,0.5453000068664551,0.5425735068321228,0.5507530069351196,0.5425735068321228,False,True,-5.035845563411721,-0.499890942761025,10068.852542166645,clinical_study,https://www.globenewswire.com/news-release/2025/06/11/3097455/25416/en/Vaxart-Reports-Positive-Clinical-Data-Demonstrating-that-its-Second-Generation-Vaccine-Technology-Produces-Much-Stronger-Antibody-Responses-than-its-First-Generation-Technology.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 08:00:00+00:00,pre_market,2025-06-11 10:26:00-04:00,2025-06-11 14:27:00+00:00,PCRX,LONG,40,24.68600082397461,24.562570819854738,24.932860832214356,24.562570819854738,False,True,-4.937200164794859,-0.4903438742516789,10063.91534200185,clinical_study,https://www.globenewswire.com/news-release/2025/06/11/3097504/0/en/Pacira-BioSciences-Unveils-Three-Year-Clinical-Data-Following-a-Single-Local-Administration-of-Investigational-Gene-Therapy-PCRX-201-in-Patients-with-Moderate-to-Severe-Osteoarthri.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 09:00:00+00:00,pre_market,2025-06-11 10:26:00-04:00,2025-06-11 14:28:00+00:00,WINT,LONG,1447,0.6951000094413757,0.6916245093941689,0.7020510095357895,0.6916245093941689,False,True,-5.02904856830834,-0.49971093728497057,10058.886293433541,partnerships,https://www.globenewswire.com/news-release/2025/06/11/3097588/0/en/Windtree-Receives-Offer-for-Its-Preclinical-Oncology-Drug-Candidate.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 09:25:00+00:00,pre_market,2025-06-11 10:26:00-04:00,2025-06-11 14:31:00+00:00,CAPR,LONG,78,12.890000343322754,13.01890034675598,13.01890034675598,12.82555034160614,True,False,10.054200267791693,0.9995341407085088,10068.940493701333,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/11/3097631/0/en/Capricor-Therapeutics-Announces-Key-Regulatory-Updates-for-its-Duchenne-Muscular-Dystrophy-Program.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 16:18:00+00:00,regular_market,2025-06-11 12:20:00-04:00,2025-06-11 16:50:00+00:00,ALVO,LONG,100,10.062000274658203,10.162620277404786,10.162620277404786,10.011690273284913,True,False,10.062000274658267,0.9993107299573964,10079.002493975991,capital_investment,https://www.globenewswire.com/news-release/2025/06/11/3097946/0/en/Alvotech-s-Private-Placement-Completed-with-Delivery-of-SDRs-and-Shares-to-Investors.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 16:20:00+00:00,regular_market,2025-06-11 12:25:00-04:00,2025-06-11 16:50:00+00:00,ALVO,LONG,100,10.062000274658203,10.162620277404786,10.162620277404786,10.011690273284913,True,False,10.062000274658267,0.998313104959753,10089.06449425065,capital_investment,https://www.globenewswire.com/news-release/2025/06/11/3097948/0/en/Alvotech-s-Private-Placement-Completed-with-Delivery-of-SDRs-and-Shares-to-Investors.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 16:20:00+00:00,regular_market,2025-06-11 12:25:00-04:00,2025-06-11 16:41:00+00:00,ALVO,SHORT,100,10.062000274658203,10.112310276031494,9.96138027191162,10.112310276031494,False,True,-5.031000137329045,-0.49865873492988455,10084.03349411332,shares_issue,https://www.globenewswire.com/news-release/2025/06/11/3097948/0/is/%C3%96ll-br%C3%A9f-afhent-kaupendum-%C3%AD-hlutafj%C3%A1r%C3%BAtbo%C3%B0i-Alvotech.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 16:30:00+00:00,regular_market,2025-06-11 12:35:00-04:00,2025-06-11 19:19:00+00:00,DBVT,LONG,113,8.885000228881836,8.840575227737427,8.973850231170655,8.840575227737427,False,True,-5.020025129318261,-0.497819164548468,10079.013468984002,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/11/3097952/0/fr/DBV-Technologies-annonce-les-r%C3%A9sultats-de-son-Assembl%C3%A9e-G%C3%A9n%C3%A9rale-Mixte-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-11 16:30:00+00:00,regular_market,2025-06-11 12:35:00-04:00,2025-06-11 19:19:00+00:00,DBVT,LONG,113,8.885000228881836,8.840575227737427,8.973850231170655,8.840575227737427,False,True,-5.020025129318261,-0.4980671119020041,10073.993443854682,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/11/3097952/0/en/DBV-Technologies-Announces-the-Voting-Results-of-its-2025-Combined-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-12 02:01:00+00:00,after_market,2025-06-12 10:26:00-04:00,2025-06-12 14:26:00+00:00,EDIT,LONG,496,2.0299999713897705,2.050299971103668,2.050299971103668,2.0198499715328215,True,False,10.068799858093165,0.9994844561106313,10084.062243712775,clinical_study,https://www.globenewswire.com/news-release/2025/06/12/3098060/0/en/Editas-Medicine-Reports-Proprietary-Targeted-Lipid-Nanoparticle-Delivery-in-Non-Human-Primates-Enables-In-Vivo-HBG1-2-Promoter-Editing-for-Sickle-Cell-Disease-and-Beta-Thalassemia-.html,e0f76d50,2025-06-28 11:19:39
2025-06-12 06:45:00+00:00,pre_market,2025-06-12 10:26:00-04:00,2025-06-12 14:48:00+00:00,BNTX,LONG,9,105.37000274658203,106.42370277404785,106.42370277404785,104.84315273284912,True,False,9.483300247192403,0.9404246044896305,10093.545543959968,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/12/3098162/0/de/BioNTech-k%C3%BCndigt-strategische-Transaktion-zur-%C3%9Cbernahme-von-CureVac-im-Rahmen-eines-%C3%B6ffentlichen-Umtauschangebots-an.html,e0f76d50,2025-06-28 11:19:39
2025-06-12 06:45:00+00:00,pre_market,2025-06-12 10:26:00-04:00,2025-06-12 14:48:00+00:00,BNTX,LONG,9,105.37000274658203,106.42370277404785,106.42370277404785,104.84315273284912,True,False,9.483300247192403,0.9395410369815252,10103.028844207161,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/12/3098162/0/en/BioNTech-Announces-Strategic-Transaction-to-Acquire-CureVac-in-Public-Exchange-Offer.html,e0f76d50,2025-06-28 11:19:39
2025-06-12 16:05:00+00:00,regular_market,2025-06-12 12:10:00-04:00,2025-06-12 16:42:00+00:00,DBVT,SHORT,105,9.604999542236328,9.65302453994751,9.508949546813964,9.65302453994751,False,True,-5.042624759674013,-0.49912009927253986,10097.986219447488,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/12/3098722/0/fr/DBV-Technologies-participera-au-prochain-congr%C3%A8s-EAACI-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-12 16:05:00+00:00,regular_market,2025-06-12 12:10:00-04:00,2025-06-12 16:42:00+00:00,DBVT,LONG,105,9.604999542236328,9.701049537658692,9.701049537658692,9.556974544525147,True,False,10.085249519348212,0.9987386890987484,10108.071468966837,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/12/3098722/0/en/DBV-Technologies-to-Participate-in-Upcoming-EAACI-Congress-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-13 08:30:00+00:00,pre_market,2025-06-13 10:26:00-04:00,2025-06-13 14:27:00+00:00,TLSA,LONG,644,1.5678000450134277,1.5599610447883605,1.583478045463562,1.5599610447883605,False,True,-5.0483161449432945,-0.4994341562030221,10103.023152821894,clinical_study,https://www.globenewswire.com/news-release/2025/06/13/3099003/0/en/Tiziana-Life-Sciences-to-Present-at-the-Bio-International-Convention.html,e0f76d50,2025-06-28 11:19:39
2025-06-13 09:00:00+00:00,pre_market,2025-06-13 10:26:00-04:00,2025-06-13 14:47:00+00:00,RAPT,LONG,1010,0.9995999932289124,1.0095959931612015,1.0095959931612015,0.9946019932627678,True,False,10.09595993161206,0.9993008804292544,10113.119112753506,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/13/3099033/0/en/RAPT-Therapeutics-Announces-Effective-Date-for-1-for-8-Reverse-Stock-Split.html,e0f76d50,2025-06-28 11:19:39
2025-06-13 10:30:00+00:00,pre_market,2025-06-13 10:26:00-04:00,2025-06-13 14:27:00+00:00,TLSA,LONG,645,1.5678000450134277,1.5599610447883605,1.583478045463562,1.5599610447883605,False,True,-5.056155145168361,-0.49996001122859496,10108.062957608337,clinical_study,https://www.globenewswire.com/news-release/2025/06/13/3099102/0/en/Tiziana-Life-Sciences-Expands-Phase-2-Clinical-Trial-of-Intranasal-Foralumab-with-Commencement-of-First-Patient-Dosing-at-Weill-Cornell-Multiple-Sclerosis-Center.html,e0f76d50,2025-06-28 11:19:39
2025-06-13 16:52:00+00:00,regular_market,2025-06-13 12:55:00-04:00,2025-06-13 16:58:00+00:00,VXRT,LONG,1490,0.6782000064849854,0.6748090064525604,0.6849820065498352,0.6748090064525604,False,True,-5.052590048313227,-0.49985739795082523,10103.010367560024,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/13/3099312/25416/en/Vaxart-Announces-Preliminary-Results-of-Annual-Meeting-of-Stockholders.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 07:02:00+00:00,pre_market,2025-06-16 10:26:00-04:00,2025-06-16 14:27:00+00:00,OCGN,SHORT,833,1.2120000123977661,1.2180600124597547,1.1998800122737885,1.2180600124597547,False,True,-5.047980051636496,-0.49965108101295874,10097.962387508387,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099710/0/en/Ocugen-Inc-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Amendment-to-Initiate-Phase-2-3-Pivotal-Confirmatory-Clinical-Trial-of-OCU410ST-Modifier-Gene-Therapy-Candidate-f.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 08:00:00+00:00,pre_market,2025-06-16 10:26:00-04:00,2025-06-16 14:33:00+00:00,XFOR,LONG,364,2.7699999809265137,2.7561499810218812,2.797699980735779,2.7561499810218812,False,True,-5.041399965286203,-0.49924923185717457,10092.9209875431,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099765/0/en/X4-Pharmaceuticals-Presents-Positive-Phase-2-Chronic-Neutropenia-Trial-Data-in-Poster-Presentations-at-the-30th-Annual-Congress-of-the-European-Hematology-Association-EHA.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 08:00:00+00:00,pre_market,2025-06-16 10:26:00-04:00,2025-06-16 14:38:00+00:00,IMRX,LONG,462,2.180000066757202,2.201800067424774,2.201800067424774,2.169100066423416,True,False,10.071600308418283,0.9978875610785883,10102.992587851519,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099746/0/en/Immuneering-to-Provide-Updates-from-Phase-2a-Clinical-Trial-of-IMM-1-104-in-First-Line-Pancreatic-Cancer-Patients-on-Tuesday-June-17-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 08:00:00+00:00,pre_market,2025-06-16 10:26:00-04:00,2025-06-16 14:30:00+00:00,MBX,SHORT,99,10.140000343322754,10.190700345039367,10.038600339889527,10.190700345039367,False,True,-5.019300169944735,-0.4968132091851934,10097.973287681574,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099759/0/en/MBX-Biosciences-Announces-IND-Submission-of-MBX-4291-its-Long-acting-GLP1-GIP-Receptor-Co-agonist-Prodrug-for-the-Treatment-of-Obesity.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 08:00:00+00:00,pre_market,2025-06-16 10:26:00-04:00,2025-06-16 14:32:00+00:00,WINT,LONG,1829,0.5519999861717224,0.5575199860334397,0.5575199860334397,0.5492399862408638,True,False,10.096079747080852,0.9998124831046016,10108.069367428656,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099771/0/en/Windtree-Announces-Publication-of-Istaroxime-Positive-Phase-2-SEISMiC-B-Study.html,e0f76d50,2025-06-28 11:19:39
2025-06-16 19:20:00+00:00,regular_market,2025-06-16 15:25:00-04:00,2025-06-16 19:40:00+00:00,PYPD,LONG,275,3.6700000762939453,3.6516500759124755,3.706700077056885,3.6516500759124755,False,True,-5.046250104904204,-0.49922986492007976,10103.023117323752,financing_agreements,https://www.globenewswire.com/news-release/2025/06/16/3100290/0/en/PolyPid-Secures-26-7-Million-Through-Warrant-Exercise-Following-Successful-SHIELD-II-Phase-3-Trial-Results.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 06:00:00+00:00,pre_market,2025-06-17 10:26:00-04:00,2025-06-17 14:27:00+00:00,IMRX,LONG,467,2.1593000888824463,2.148503588438034,2.1808930897712706,2.148503588438034,False,True,-5.041965707540479,-0.49905514903702153,10097.981151616212,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100460/0/en/Immuneering-Reports-Positive-Overall-Survival-Data-for-Atebimetinib-IMM-1-104-from-Ongoing-Phase-2a-Trial-in-First-Line-Pancreatic-Cancer-Patients.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 07:00:00+00:00,pre_market,2025-06-17 10:26:00-04:00,2025-06-17 14:34:00+00:00,MLYS,LONG,72,13.845000267028809,13.775775265693664,13.983450269699096,13.775775265693664,False,True,-4.984200096130422,-0.49358381851729694,10092.996951520081,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100518/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-Explore-CKD-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-CKD-and-Albuminuria.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 08:00:00+00:00,pre_market,2025-06-17 10:26:00-04:00,2025-06-17 15:01:00+00:00,ELTX,LONG,124,8.079999923706055,8.039599924087524,8.160799922943115,8.039599924087524,False,True,-5.009599952697833,-0.49634414602130145,10087.987351567383,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/17/3100565/0/en/Elicio-Therapeutics-to-Host-Virtual-KOL-Event-on-June-25-2025-to-Discuss-AMP-Powered-ELI-002-for-the-Treatment-of-KRAS-mutation-driven-Pancreatic-Cancer.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 08:05:00+00:00,pre_market,2025-06-17 10:26:00-04:00,2025-06-17 14:30:00+00:00,IMNN,LONG,877,1.149399995803833,1.1436529958248138,1.1608939957618714,1.1436529958248138,False,True,-5.040118981599815,-0.49961591008703293,10082.947232585782,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100614/0/en/IMUNON-Announces-PlaCCine-DNA-Vaccine-Technology-Abstract-Selected-for-Oral-Presentation-at-10th-International-Conference-on-Vaccines-Research-Development.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 09:00:00+00:00,pre_market,2025-06-17 10:26:00-04:00,2025-06-17 14:42:00+00:00,CAPR,LONG,83,12.029999732971191,12.150299730300903,12.150299730300903,11.969849734306335,True,False,9.984899778366048,0.9902759131870821,10092.932132364149,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/17/3100690/0/en/Capricor-Therapeutics-Announces-Orphan-Drug-Designation-for-Becker-Muscular-Dystrophy-and-Regulatory-Progress-for-Duchenne-Muscular-Dystrophy-Program.html,e0f76d50,2025-06-28 11:19:39
2025-06-17 14:55:00+00:00,regular_market,2025-06-17 11:00:00-04:00,2025-06-17 15:00:00+00:00,EYEN,LONG,238,4.230100154876709,4.2724011564254765,4.2724011564254765,4.208949654102326,True,False,10.06763836860666,0.9974939132230582,10102.999770732755,financing_agreements,https://www.globenewswire.com/news-release/2025/06/17/3101041/0/en/Eyenovia-Announces-50-Million-Investment-to-Launch-a-Hyperliquid-HYPE-token-Cryptocurrency-Treasury-Reserve-Strategy.html,e0f76d50,2025-06-28 11:19:39
2025-06-18 01:00:00+00:00,after_market,2025-06-18 10:26:00-04:00,2025-06-18 15:55:00+00:00,ADXN,LONG,123,8.199999809265137,8.281999807357789,8.281999807357789,8.15899981021881,True,False,10.08599976539617,0.9983173309192948,10113.085770498152,financial_results,https://www.globenewswire.com/news-release/2025/06/18/3101159/0/en/Addex-Therapeutics-to-Release-Q1-2025-Financial-Results-and-Host-Conference-Call-on-June-19-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-18 08:00:00+00:00,pre_market,2025-06-18 10:26:00-04:00,2025-06-18 17:06:00+00:00,PCRX,SHORT,41,24.584999084472656,24.33914909362793,24.33914909362793,24.707924079895015,True,False,10.07984962463373,0.996713550481162,10123.165620122785,feature_article,https://www.globenewswire.com/news-release/2025/06/18/3101383/0/en/Pacira-BioSciences-Debuts-Inspiring-New-Film-Highlighting-One-Patient-s-Journey-to-Pain-Relief-and-Innovation-in-Care-at-BIO-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-18 08:05:00+00:00,pre_market,2025-06-18 10:26:00-04:00,2025-06-18 14:48:00+00:00,IMNN,LONG,1033,0.9794999957084656,0.9746024957299232,0.9892949956655502,0.9746024957299232,False,True,-5.059117477834285,-0.4997564662755089,10118.10650264495,clinical_study,https://www.globenewswire.com/news-release/2025/06/18/3101425/0/en/IMUNON-Presents-Positive-Phase-2-Translational-Data-of-IMNN-001-in-Advanced-Ovarian-Cancer-at-ESMO-Gynaecological-Cancers-Congress-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-18 08:32:00+00:00,pre_market,2025-06-18 10:26:00-04:00,2025-06-18 14:27:00+00:00,EYEN,LONG,196,5.150000095367432,5.124250094890594,5.201500096321106,5.124250094890594,False,True,-5.0470000934601735,-0.49880875360828125,10113.05950255149,financing_agreements,https://www.globenewswire.com/news-release/2025/06/18/3101458/0/en/Eyenovia-Announces-Appointment-of-a-Strategic-Advisor-for-Digital-Asset-Treasury-Strategy-and-Amendment-of-Debt-Agreement-with-Avenue-Capital-Group.html,e0f76d50,2025-06-28 11:19:39
2025-06-18 16:05:00+00:00,regular_market,2025-06-18 12:10:00-04:00,2025-06-18 16:22:00+00:00,ANNX,LONG,416,2.430999994277954,2.418844994306564,2.4553099942207335,2.418844994306564,False,True,-5.056479988098204,-0.49999507931526266,10108.003022563393,clinical_study,https://www.globenewswire.com/news-release/2025/06/18/3101903/0/en/Annexon-Bolsters-Ophthalmology-Expertise-with-Appointment-of-Retina-Specialist-Lloyd-Clark-M-D-as-Pivotal-ANX007-Program-Advances-in-Dry-Age-Related-Macular-Degeneration-AMD-with-G.html,e0f76d50,2025-06-28 11:19:39
2025-06-19 01:00:00+00:00,after_market,2025-06-20 10:26:00-04:00,2025-06-20 15:09:00+00:00,ADXN,LONG,114,8.819999694824219,8.775899696350098,8.908199691772461,8.775899696350098,False,True,-5.027399826049724,-0.49736825511700067,10102.975622737344,financial_results,https://www.globenewswire.com/news-release/2025/06/19/3102000/0/en/Addex-Therapeutics-Reports-Q1-2025-Financial-Results-and-Provides-Corporate-Update.html,e0f76d50,2025-06-28 11:19:39
2025-06-20 09:25:00+00:00,pre_market,2025-06-20 10:26:00-04:00,2025-06-20 14:28:00+00:00,CAPR,LONG,102,9.819999694824219,9.918199691772461,9.918199691772461,9.770899696350098,True,False,10.016399688720718,0.991430650013469,10112.992022426064,clinical_study,https://www.globenewswire.com/news-release/2025/06/20/3102761/0/en/Capricor-Therapeutics-Announces-Positive-4-Year-Data-from-HOPE-2-Open-Label-Extension-Study-of-Deramiocel-in-Duchenne-Muscular-Dystrophy.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 04:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:39:00+00:00,ALVO,LONG,110,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,False,True,-5.032499790191611,-0.4976271887718087,10107.959522635872,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/23/3103152/0/is/Lyfjastofnun-Evr%C3%B3pu-m%C3%A6lir-me%C3%B0-%C3%BEv%C3%AD-a%C3%B0-veita-marka%C3%B0sleyfi-fyrir-AVT06-fyrirhuga%C3%B0a-hli%C3%B0st%C3%A6%C3%B0u-Alvotech-vi%C3%B0-augnlyfi%C3%B0-Eylea.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 04:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:39:00+00:00,ALVO,LONG,110,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,False,True,-5.032499790191611,-0.4978749448809898,10102.92702284568,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/23/3103152/0/en/European-Medicines-Agency-Recommends-Market-Approval-of-AVT06-Alvotech-s-Proposed-Biosimilar-to-Eylea-aflibercept.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 04:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:39:00+00:00,ALVO,LONG,110,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,False,True,-5.032499790191611,-0.4981229478161778,10097.89452305549,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/23/3103150/0/en/European-Medicines-Agency-Recommends-Market-Approval-of-AVT06-Alvotech-s-Proposed-Biosimilar-to-Eylea-aflibercept.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 07:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:35:00+00:00,CDTX,LONG,24,40.529998779296875,40.32734878540039,40.93529876708985,40.32734878540039,False,True,-4.863599853515666,-0.48164494513297856,10093.030923201974,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103267/0/en/Cidara-Therapeutics-Announces-Positive-Topline-Results-from-its-Phase-2b-NAVIGATE-Trial-Evaluating-CD388-a-Non-Vaccine-Preventative-of-Seasonal-Influenza.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 07:30:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:38:00+00:00,OCGN,LONG,996,1.0132999420166016,1.0082334423065185,1.0234329414367676,1.0082334423065185,False,True,-5.046233711242773,-0.49997208466313464,10087.984689490731,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/23/3103287/0/en/Carisma-Therapeutics-and-OrthoCellix-Enter-into-Definitive-Merger-Agreement-to-Create-Company-Focused-on-Regenerative-Cell-Therapies-for-Orthopedic-Diseases.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 15:57:00+00:00,IMMP,LONG,646,1.559999942779541,1.5521999430656432,1.5755999422073363,1.5521999430656432,False,True,-5.038799815177963,-0.49948527582790525,10082.945889675553,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103327/0/en/Immutep-Announces-Positive-Update-from-Phase-I-Study-of-IMP761-a-First-in-Class-LAG-3-Agonist-Antibody-for-Autoimmune-Diseases.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:30:00+00:00,RAPT,LONG,131,7.650000095367432,7.611750094890595,7.726500096321106,7.611750094890595,False,True,-5.010750062465635,-0.4969529854956774,10077.935139613088,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103308/0/en/RAPT-Therapeutics-Names-Two-Industry-Veterans-to-its-Board-of-Directors.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:00:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:50:00+00:00,MBX,LONG,103,9.739999771118164,9.837399768829346,9.837399768829346,9.691299772262573,True,False,10.032199764251782,0.9954618307492837,10087.96733937734,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103333/0/en/MBX-Biosciences-Appoints-Andreas-Moraitis-M-D-as-Senior-Vice-President-of-Clinical-Development.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:05:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 15:04:00+00:00,NKGN,LONG,4035,0.25,0.24875,0.2525,0.24875,False,True,-5.043750000000005,-0.49997683679171395,10082.923589377338,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103355/0/en/NKGen-Biotech-Announces-International-and-U-S-Expansion-of-Phase-1-2a-Troculeucel-Alzheimer-s-Trial-with-Activation-of-Clinical-Sites-in-Canada-and-Florida.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:05:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:27:00+00:00,CADL,LONG,216,4.650000095367432,4.626750094890594,4.696500096321106,4.626750094890594,False,True,-5.0220001029968415,-0.49806983643986635,10077.901589274341,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103352/0/en/Candel-Therapeutics-Appoints-Charles-Schoch-as-Chief-Financial-Officer.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 08:30:00+00:00,pre_market,2025-06-23 10:26:00-04:00,2025-06-23 14:26:00+00:00,EYEN,LONG,174,5.770699977874756,5.741846477985382,5.828406977653503,5.741846477985382,False,True,-5.020508980751099,-0.49817007402555913,10072.88108029359,financing_agreements,https://www.globenewswire.com/news-release/2025/06/23/3103404/0/en/Eyenovia-Announces-Closing-of-50-Million-Private-Placement-Successful-Accumulation-of-More-Than-One-Million-HYPE-Tokens-and-Update-on-its-Optejet-Development-Program.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 16:05:00+00:00,regular_market,2025-06-23 12:10:00-04:00,2025-06-23 16:13:00+00:00,IOVA,LONG,532,1.8899999856948853,1.8805499857664107,1.908899985551834,1.8805499857664107,False,True,-5.027399961948437,-0.4991024833782616,10067.853680331642,corporate_action,https://www.globenewswire.com/news-release/2025/06/23/3103831/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 16:15:00+00:00,regular_market,2025-06-23 12:20:00-04:00,2025-06-23 16:28:00+00:00,CDTX,SHORT,24,41.8849983215332,41.46614833831787,41.46614833831787,42.094423313140865,True,False,10.052399597167948,0.9984650071748773,10077.906079928809,shares_issue,https://www.globenewswire.com/news-release/2025/06/23/3103844/0/en/Cidara-Announces-Proposed-Public-Offering-of-Common-Stock.html,e0f76d50,2025-06-28 11:19:39
2025-06-23 16:50:00+00:00,regular_market,2025-06-23 12:55:00-04:00,2025-06-23 16:58:00+00:00,SCLX,LONG,217,4.630000114440918,4.676300115585327,4.676300115585327,4.606850113868713,True,False,10.047100248336854,0.9969432309303509,10087.953180177146,corporate_action,https://www.globenewswire.com/news-release/2025/06/23/3103857/0/en/Scilex-Holding-Company-Announces-Deferral-of-Record-Date-for-its-Previously-Announced-Dividend-of-Preferred-Stock-Exchangeable-for-up-to-10-of-Scilex-s-Ownership-Interest-in-Semnur.html,e0f76d50,2025-06-28 11:19:39
2025-06-24 06:30:00+00:00,pre_market,2025-06-24 10:26:00-04:00,2025-06-24 14:39:00+00:00,LGVN,LONG,820,1.2300000190734863,1.2423000192642213,1.2423000192642213,1.223850018978119,True,False,10.086000156402669,0.9998064003926669,10098.03918033355,clinical_study,https://www.globenewswire.com/news-release/2025/06/24/3104065/0/en/Longeveron-Announces-Completion-of-Enrollment-of-Pivotal-Phase-2b-Clinical-Trial-Evaluating-Laromestrocel-as-a-Treatment-for-Hypoplastic-Left-Heart-Syndrome-HLHS.html,e0f76d50,2025-06-28 11:19:39
2025-06-24 09:00:00+00:00,pre_market,2025-06-24 10:26:00-04:00,2025-06-24 14:26:00+00:00,CAPR,LONG,117,8.619999885559082,8.576899886131287,8.706199884414673,8.576899886131287,False,True,-5.042699933052063,-0.49937416987576955,10092.996480400498,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/24/3104316/0/en/Capricor-Therapeutics-Provides-Regulatory-Update-on-Deramiocel-BLA-for-Duchenne-Muscular-Dystrophy.html,e0f76d50,2025-06-28 11:19:39
2025-06-24 09:05:00+00:00,pre_market,2025-06-24 10:26:00-04:00,2025-06-24 14:33:00+00:00,CADL,SHORT,208,4.849999904632568,4.801499905586243,4.801499905586243,4.874249904155731,True,False,10.087999801635661,0.9995049360440638,10103.084480202133,shares_issue,https://www.globenewswire.com/news-release/2025/06/24/3104329/0/en/Candel-Therapeutics-Announces-15-million-Registered-Direct-Offering-of-Common-Stock.html,e0f76d50,2025-06-28 11:19:39
2025-06-24 16:05:00+00:00,regular_market,2025-06-24 12:10:00-04:00,2025-06-24 17:24:00+00:00,CRBP,LONG,126,7.98330020904541,7.943383708000183,8.063133211135865,7.943383708000183,False,True,-5.029479131698649,-0.4978162007409072,10098.055001070434,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/24/3104651/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-3rd-Annual-Piper-Obesity-Symposium.html,e0f76d50,2025-06-28 11:19:39
2025-06-24 20:00:00+00:00,after_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,CDTX,SHORT,20,49.0,48.51,48.51,49.245,True,False,9.80000000000004,0.9704839198203219,10107.855001070433,shares_issue,https://www.globenewswire.com/news-release/2025/06/25/3104754/0/en/Cidara-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 01:00:00+00:00,after_market,2025-06-25 10:26:00-04:00,2025-06-25 16:56:00-04:00,ADXN,SHORT,110,9.15999984741211,9.15999984741211,9.068399848937988,9.20579984664917,False,False,0.0,0.0,10107.855001070433,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3104791/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Annual-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 04:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,ALVO,SHORT,109,9.199999809265137,9.245999808311462,9.107999811172485,9.245999808311462,False,True,-5.013999896049414,-0.496049843959814,10102.841001174384,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104830/0/en/Positive-Top-Line-Results-from-Confirmatory-Efficacy-Study-for-Proposed-Biosimilar-to-Xolair-omalizumab.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 04:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 19:45:00+00:00,ALVO,LONG,109,9.199999809265137,9.153999810218812,9.291999807357788,9.153999810218812,False,True,-5.013999896049414,-0.49629603152881185,10097.827001278334,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104830/0/is/J%C3%A1kv%C3%A6%C3%B0-ni%C3%B0ursta%C3%B0a-%C3%BAr-kl%C3%ADn%C3%ADskri-ranns%C3%B3kn-fyrir-fyrirhuga%C3%B0a-hli%C3%B0st%C3%A6%C3%B0u-Alvotech-vi%C3%B0-l%C3%ADft%C3%A6knilyfi%C3%B0-Xolair.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 04:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,ALVO,SHORT,109,9.199999809265137,9.245999808311462,9.107999811172485,9.245999808311462,False,True,-5.013999896049414,-0.49654246358297355,10092.813001382285,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104833/0/en/Positive-Top-Line-Results-from-Confirmatory-Efficacy-Study-for-Proposed-Biosimilar-to-Xolair-omalizumab.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:29:00+00:00,EVAX,LONG,423,2.3819000720977783,2.4057190728187563,2.4057190728187563,2.3699905717372896,True,False,10.075437304973685,0.9982784089622764,10102.888438687258,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105043/0/en/Evaxion-expands-R-D-pipeline-with-new-vaccine-program-targeting-Group-A-Streptococcus.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 15:51:00+00:00,ENTX,LONG,510,1.979099988937378,1.9988909888267516,1.9988909888267516,1.969204488992691,True,False,10.093409943580596,0.9990618034471839,10112.981848630838,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105034/0/en/OPKO-Health-and-Entera-Bio-Abstract-for-First-in-Class-Dual-GLP-1-Glucagon-Tablet-Candidate-for-Patients-with-Obesity-and-Metabolic-Disorders-Selected-for-Presentation-at-the-ENDO-.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 15:14:00+00:00,CRBP,LONG,126,7.965000152587891,8.04465015411377,8.04465015411377,7.925175151824951,True,False,10.035900192260751,0.9923779496963575,10123.017748823098,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105004/0/en/Corbus-Pharmaceuticals-Announces-First-Patient-Dosed-with-its-Nectin-4-Targeting-ADC-CRB-701-in-Combination-with-Pembrolizumab.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,OVID,LONG,3374,0.30000001192092896,0.2985000118613243,0.30300001204013827,0.2985000118613243,False,True,-5.061000201106109,-0.49994975082351306,10117.956748621993,mergers_acquisitions,https://www.globenewswire.com/news-release/2025/06/25/3105008/0/en/Ovid-Therapeutics-Enters-Agreement-with-Immedica-Pharma-AB-for-Sale-of-Future-Ganaxolone-Royalties.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 16:25:00+00:00,BCDA,LONG,466,2.1700000762939453,2.1591500759124758,2.191700077056885,2.1591500759124758,False,True,-5.05610017776481,-0.49971553579268074,10112.900648444229,patents,https://www.globenewswire.com/news-release/2025/06/25/3105029/0/en/BioCardia-Announces-New-United-States-Patent-for-Helix-Biotherapeutic-Delivery-System.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:00:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,ICCC,LONG,141,7.130000114440918,7.094350113868713,7.201300115585327,7.094350113868713,False,True,-5.026650080680892,-0.4970532447042475,10107.873998363548,management_changes,https://www.globenewswire.com/news-release/2025/06/25/3105042/0/en/ImmuCell-Embarks-on-CEO-Succession-Planning-Process.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:01:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:38:00+00:00,MYNZ,LONG,721,1.399999976158142,1.4139999759197235,1.4139999759197235,1.3929999762773513,True,False,10.093999828100186,0.9986273898679774,10117.967998191649,government_news,https://www.globenewswire.com/news-release/2025/06/25/3105048/0/en/Mainz-Biomed-Secures-Public-Funding-to-Advance-Innovative-Pancreatic-Cancer-Screening-Test.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 08:30:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 14:26:00+00:00,EYEN,LONG,96,10.470000267028809,10.417650265693664,10.574700269699097,10.417650265693664,False,True,-5.025600128173835,-0.49670053602383835,10112.942398063475,partnerships,https://www.globenewswire.com/news-release/2025/06/25/3105095/0/en/Eyenovia-Announces-Co-Branded-Validator-with-Kinetiq.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 11:45:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 16:07:00+00:00,VALN,LONG,176,5.714099884033203,5.685529384613037,5.771240882873535,5.685529384613037,False,True,-5.028407897949194,-0.4972250112798114,10107.913990165525,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3105296/0/en/Valneva-Announces-Successful-Outcome-of-its-Annual-General-Meeting-Confirms-FY-2025-guidance.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 11:45:00+00:00,pre_market,2025-06-25 10:26:00-04:00,2025-06-25 16:07:00+00:00,VALN,LONG,176,5.714099884033203,5.685529384613037,5.771240882873535,5.685529384613037,False,True,-5.028407897949194,-0.49747236698309594,10102.885582267576,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3105296/0/fr/Valneva-annonce-l-approbation-des-r%C3%A9solutions-pr%C3%A9sent%C3%A9es-%C3%A0-son-Assembl%C3%A9e-G%C3%A9n%C3%A9rale-annuelle-et-confirme-ses-perspectives-financi%C3%A8res-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 16:15:00+00:00,regular_market,2025-06-25 12:20:00-04:00,2025-06-25 16:49:00+00:00,DBVT,SHORT,114,8.819999694824219,8.86409969329834,8.731799697875976,8.86409969329834,False,True,-5.027399826049724,-0.4976201883226051,10097.858182441527,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105444/0/en/DBV-Technologies-Announces-First-Subject-Screened-in-COMFORT-Toddlers-Supplemental-Safety-Study-in-Peanut-Allergic-Toddlers-1-3-Years-Old.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 16:15:00+00:00,regular_market,2025-06-25 12:20:00-04:00,2025-06-25 16:49:00+00:00,DBVT,SHORT,114,8.819999694824219,8.86409969329834,8.731799697875976,8.86409969329834,False,True,-5.027399826049724,-0.49786793745940344,10092.830782615478,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105444/0/fr/DBV-Technologies-annonce-le-screening-du-premier-sujet-de-l-%C3%A9tude-compl%C3%A9mentaire-d-innocuit%C3%A9-COMFORT-Toddlers-chez-les-enfants-%C3%A2g%C3%A9s-de-1-%C3%A0-3-ans-allergiques-%C3%A0-l-arachide.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 16:45:00+00:00,regular_market,2025-06-25 12:50:00-04:00,2025-06-25 17:44:00+00:00,ALVO,LONG,109,9.210000038146973,9.163950037956237,9.302100038528442,9.163950037956237,False,True,-5.0194500207901775,-0.49732826487450793,10087.811332594687,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3105464/0/is/Ni%C3%B0ursta%C3%B0a-a%C3%B0alfundar-Alvotech-%C3%A1ri%C3%B0-2025.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 16:45:00+00:00,regular_market,2025-06-25 12:50:00-04:00,2025-06-25 17:44:00+00:00,ALVO,LONG,109,9.210000038146973,9.163950037956237,9.302100038528442,9.163950037956237,False,True,-5.0194500207901775,-0.4975757233456431,10082.791882573896,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3105463/0/en/Main-Results-of-2025-Annual-and-Extraordinary-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-25 16:45:00+00:00,regular_market,2025-06-25 12:50:00-04:00,2025-06-25 17:44:00+00:00,ALVO,LONG,109,9.210000038146973,9.163950037956237,9.302100038528442,9.163950037956237,False,True,-5.0194500207901775,-0.49782342819802716,10077.772432553105,annual_general_meeting,https://www.globenewswire.com/news-release/2025/06/25/3105464/0/en/Main-Results-of-2025-Annual-and-Extraordinary-General-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 01:00:00+00:00,after_market,2025-06-26 10:26:00-04:00,2025-06-26 16:43:00+00:00,VALN,LONG,174,5.78000020980835,5.751100208759308,5.837800211906433,5.751100208759308,False,True,-5.028600182533289,-0.4989793345888583,10072.743832370572,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3105549/0/en/Valneva-Announces-Exclusive-Vaccine-Marketing-and-Distribution-Agreement-for-Germany-with-CSL-Seqirus.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 01:00:00+00:00,after_market,2025-06-26 10:26:00-04:00,2025-06-26 16:43:00+00:00,VALN,LONG,174,5.78000020980835,5.751100208759308,5.837800211906433,5.751100208759308,False,True,-5.028600182533289,-0.4992284392632898,10067.715232188038,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3105549/0/fr/Valneva-annonce-un-accord-exclusif-avec-CSL-Seqirus-pour-le-marketing-et-la-distribution-de-ses-vaccins-en-Allemagne.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 04:15:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:29:00+00:00,ALVO,LONG,106,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,False,True,-5.021750202179053,-0.49879740202858963,10062.69348198586,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/en/Alvotech-s-Lenders-Lower-Interest-on-Senior-Secured-Term-Loan-Facility.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 04:15:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:29:00+00:00,ALVO,LONG,106,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,False,True,-5.021750202179053,-0.49904632503901103,10057.671731783681,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/sv/Alvotechs-l%C3%A5ngivare-s%C3%A4nker-r%C3%A4ntan-p%C3%A5-senior-s%C3%A4kerst%C3%A4lld-l%C3%A5nefacilitet.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 04:15:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:29:00+00:00,ALVO,LONG,106,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,False,True,-5.021750202179053,-0.4992954966217085,10052.649981581502,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105606/0/en/Alvotech-s-Lenders-Lower-Interest-on-Senior-Secured-Term-Loan-Facility.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 04:15:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:29:00+00:00,ALVO,LONG,106,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,False,True,-5.021750202179053,-0.4995449171492014,10047.628231379324,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/is/L%C3%A1nveitendur-Alvotech-l%C3%A6kka-vexti-%C3%A1-langt%C3%ADmaskuldum-f%C3%A9lagsins.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 07:00:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:04:00+00:00,CRSP,LONG,21,46.099998474121094,46.56099845886231,46.56099845886231,45.86949848175049,True,False,9.680999679565495,0.9635109357779753,10057.309231058889,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105698/0/en/CRISPR-Therapeutics-Reports-Positive-Additional-Phase-1-Data-for-CTX310-Targeting-ANGPTL3-and-Provides-Update-on-In-Vivo-Cardiovascular-Pipeline.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 07:00:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 19:06:00+00:00,RVVTF,LONG,67048,0.014999999664723873,0.015149999661371111,0.015149999661371111,0.014924999666400254,True,False,10.057199775204035,0.9999891167853807,10067.366430834094,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105718/0/en/Revive-Therapeutics-Nears-Completion-of-Key-Nerve-Agent-Countermeasure-Study-with-Canadian-Department-of-National-Defence-Highlighting-Significant-Stockpiling-Opportunity.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 08:00:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 15:19:00+00:00,ENTX,LONG,505,1.9900000095367432,2.0099000096321107,2.0099000096321107,1.9800500094890594,True,False,10.049500048160597,0.99822531713768,10077.415930882255,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105791/0/en/Entera-Bio-Data-for-EB613-Effects-on-Trabecular-and-Cortical-Bone-in-Post-Menopausal-Women-with-Osteoporosis-Selected-for-Oral-Presentation-at-ASBMR-2025-Annual-Meeting.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 08:00:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 14:38:00+00:00,ANVS,LONG,449,2.2411000728607178,2.263511073589325,2.263511073589325,2.229894572496414,True,False,10.062539327144702,0.9985237680135872,10087.478470209398,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/26/3105798/0/en/Annovis-to-Attend-the-AAIC-2025-with-Four-Poster-Presentations.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 08:00:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 14:43:00+00:00,ARQT,LONG,69,14.454999923706055,14.382724924087524,14.599549922943115,14.382724924087524,False,True,-4.986974973678594,-0.4943727997443818,10082.49149523572,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/26/3105808/0/en/Arcutis-ZORYVE-roflumilast-Cream-0-15-Receives-Strong-Recommendation-in-American-Academy-of-Dermatology-Updated-Guidelines-for-Adult-Atopic-Dermatitis.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 08:19:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 14:52:00+00:00,BMRA,LONG,329,3.059999942779541,3.0446999430656434,3.0905999422073362,3.0446999430656434,False,True,-5.033699905872316,-0.49925158957494686,10077.457795329847,management_changes,https://www.globenewswire.com/news-release/2025/06/26/3105827/0/en/Clinical-Diagnostics-Industry-Leader-Scott-Madel-Joins-Biomerica-s-Team-as-Chief-Commercial-Officer.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 09:05:00+00:00,pre_market,2025-06-26 10:26:00-04:00,2025-06-26 14:35:00+00:00,LGVN,LONG,763,1.3200000524520874,1.313400052189827,1.3332000529766084,1.313400052189827,False,True,-5.035800200104666,-0.4997093813122577,10072.421995129742,management_changes,https://www.globenewswire.com/news-release/2025/06/26/3105920/0/en/Longeveron-Appoints-Than-Powell-as-Chief-Business-Officer.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 16:00:00+00:00,regular_market,2025-06-26 12:05:00-04:00,2025-06-26 16:16:00+00:00,INMB,LONG,159,6.300000190734863,6.363000192642212,6.363000192642212,6.2685001897811885,True,False,10.01700030326844,0.9944976797151568,10082.43899543301,conference_call_webinar,https://www.globenewswire.com/news-release/2025/06/26/3106204/0/en/INmune-Bio-Inc-to-Announce-Top-Line-Results-from-MINDFuL-Phase-2-Trial-in-Early-Alzheimer-s-on-Monday-June-30th.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 16:05:00+00:00,regular_market,2025-06-26 12:10:00-04:00,2025-06-26 16:12:00+00:00,WINT,LONG,2335,0.4316999912261963,0.43601699113845827,0.43601699113845827,0.4295414912700653,True,False,10.080194795131714,0.999777414938755,10092.519190228142,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3106221/0/en/Windtree-Advances-Lower-Cost-Manufacturing-of-PHEXXI-Evofem-s-Hormone-Free-On-Demand-Prescription-Contraceptive-Gel.html,e0f76d50,2025-06-28 11:19:39
2025-06-26 17:15:00+00:00,regular_market,2025-06-26 13:20:00-04:00,2025-06-26 17:22:00+00:00,CDTX,SHORT,21,47.79999923706055,48.038999233245846,47.32199924468994,48.038999233245846,False,True,-5.018999919891286,-0.49729902171014156,10087.50019030825,shares_issue,https://www.globenewswire.com/news-release/2025/06/26/3106294/0/en/Cidara-Announces-Closing-of-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,e0f76d50,2025-06-28 11:19:39
2025-06-27 12:16:00+00:00,pre_market,2025-06-27 10:26:00-04:00,2025-06-27 14:26:00+00:00,INMB,LONG,93,10.767600059509277,10.87527606010437,10.87527606010437,10.713762059211732,True,False,10.013868055343687,0.9927006559033024,10097.514058363595,financing_agreements,https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,e0f76d50,2025-06-28 11:19:39
